2024
Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areas
2015
Screening and referral for axial spondyloarthritis—need of the hour
Danve A, Deodhar A. Screening and referral for axial spondyloarthritis—need of the hour. Clinical Rheumatology 2015, 34: 987-993. PMID: 25946983, DOI: 10.1007/s10067-015-2958-2.Peer-Reviewed Original ResearchConceptsChronic back painBack painReferral strategiesMechanical back painSelection of patientsPrimary care physiciansRehabilitation medicine physiciansManagement of axSpAEffective therapeutic agentAge of onsetPrompt diagnosisCare physiciansRheumatoid arthritisAxial spondyloarthritisAppropriate treatmentClinical studiesReferring providerEarly diagnosisMedicine physiciansGeneral populationSpondyloarthritis featuresSpine surgeonsPatientsPhysical therapistsPain